参考文献/References:
[1] Lopes LR, Zekavati A, Syrris P, et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequen-cing[J]. J Med Genet, 2013, 50: 228-239.
[2] McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: an important cause of sudden death[J]. Arch Dis Child, 1984, 59: 971-975.
[3] McKenna WJ, Krikler DM, Goodwin JF. Arrhythmias in dilated and hypertrophic cardiomyopathy[J]. Med Clin North Am, 1984, 68: 983-1000.
[4] Maron BJ, Maron MS. Hypertrophic cardiomyopathy[J]. Lancet,2013, 381: 242-55.
[5] 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识组. 肥厚型梗阻性心肌病室间隔心肌消融术中国专家共识[J]. 中国医药科学. 2012, 10: 3-4.
[6] Lawrenz T, Borchert B, Leuner C, et al. Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyo-pathy: acute results and 6 months’ follow-up in 19 patients[J]. J Am Coll Cardiol, 2011, 57: 572-576.
[7] Sreeram N, Emmel M, De Giovanni JV. Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children[J]. J Am Coll Cardiol, 2011, 58: 2501-2510.
[8] 石蕴琦, 李占全. 梗阻性肥厚型心肌病介入治疗与手术治疗的比较[J]. 中国介入心脏病学杂志, 2015, 23: 291-293.
[9] Towbin JA. Hypertrophic cardiomyopathy[J]. Pacing Clin Electro-physiol, 2009, 32(Suppl 2): S23-S31.
[10] Gersh BJ, Maron BJ, Bonow RO. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy (vol 42, pg 1687, 2003)[J]. J Am Coll Cardiol, 2012, 59: 434.
[11] Maron BJ. Hypertrophic cardiomyopathy: a systematic review[J]. JAMA, 2002, 287: 1308-1320.
[12] Kuhn H, Seggewiss H, Gietzen FH, et al. Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry[J]. Z Kardiol, 2004, 93: 23-31.
[13] Zeng Z, Wang F, Dou X, et al. Comparison of percutaneous transluminal septal myocardial ablation versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a meta analysis[J]. Int J Cardiol, 2006, 112: 80-84.
[14] Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy(TASH): a 10 year experience[J]. Clin Res Cardiol, 2008, 97: 234-243.
[15] Maron BJ. Hypertrophic cardiomyopathy in childhood[J]. Pediatr Clin North Am, 2004, 51: 1305-1346.
[16] Hsieh TC, Patel K. Echocardiography-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy[J]. Anesth Analg, 2011, 113: 44-46.
[17] Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy[J]. Circulation, 2008, 117: 429-439.
[18] Yamane T, Jais P, Shah DC, et al. Efficacy and safety of an irrigated-tip catheter for the ablation of accessory pathways resistant to conventional radiofrequency ablation[J]. Circulation, 2000, 102: 2565-2568.
相似文献/References:
[1]吴 弘,王启平,秦永文,等. 经皮腔内室间隔心肌消融术治疗肥厚型梗阻性心肌病的长期疗效及安全性观察[J].介入放射学杂志,2014,(02):104.
WU Hong,WANG Qi? ping,QIN Yong? wen,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: its long?蛳 term efficacy and safety[J].journal interventional radiology,2014,(02):104.